Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Buda

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of TherapyCyrille Touzeau, Roberto Mina, Hang Quach, et al.
Hemasphere|January 24, 2025
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL studySonia Morè, Irene Federici, Alessandra Bossi, et al.
International Journal of Cancer|October 9, 2016
Identification of miRSNPs associated with the risk of multiple myelomaAngelica Macauda, Diego Calvetti, Giuseppe Maccari, et al.
International Journal of Cancer|March 6, 2021
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patientsAngelica Macauda, Chiara Piredda, Alyssa I Clay-Gilmour, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 14, 2022
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?Angelica Macauda, Alyssa Clay-Gilmour, Thomas Hielscher, et al.
Haematologica|August 5, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
Haematologica|March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
International Journal of Cancer|September 9, 2022
A pleiotropic variant in DNAJB4 is associated with multiple myeloma riskMarco Dicanio, Matteo Giaccherini, Alyssa Clay-Gilmour, et al.
Haematologica|November 28, 2024
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trialsEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Leukemia|September 18, 2023
Identification of novel genetic loci for risk of multiple myeloma by functional annotationAngelica Macauda, Klara Briem, Alyssa Clay-Gilmour, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of TherapyCyrille Touzeau, Roberto Mina, Hang Quach, et al.
Hemasphere|January 24, 2025
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL studySonia Morè, Irene Federici, Alessandra Bossi, et al.
International Journal of Cancer|October 9, 2016
Identification of miRSNPs associated with the risk of multiple myelomaAngelica Macauda, Diego Calvetti, Giuseppe Maccari, et al.
International Journal of Cancer|March 6, 2021
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patientsAngelica Macauda, Chiara Piredda, Alyssa I Clay-Gilmour, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 14, 2022
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?Angelica Macauda, Alyssa Clay-Gilmour, Thomas Hielscher, et al.
Haematologica|August 5, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
Haematologica|March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.
International Journal of Cancer|September 9, 2022
A pleiotropic variant in DNAJB4 is associated with multiple myeloma riskMarco Dicanio, Matteo Giaccherini, Alyssa Clay-Gilmour, et al.
Haematologica|November 28, 2024
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trialsEnrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Leukemia|September 18, 2023
Identification of novel genetic loci for risk of multiple myeloma by functional annotationAngelica Macauda, Klara Briem, Alyssa Clay-Gilmour, et al.
Pageof 14